Skip to main content
OpenTrials

Clinical trial condition

Refractory Non-Hodgkin Lymphoma

Explore clinical trials studying Refractory Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

54 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Refractory Non-Hodgkin Lymphoma trial results

Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527

Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Illinois at Chicago Chicago, Illinois, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
View Trial Details
Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

NCT07188558

Conditions
Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, +16 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Honor Health Scottsdale, Arizona, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • University of Arkansas Little Rock, Arkansas, United States
View all 38 locations
View Trial Details
Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT05826535

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations
  • University of California-Irvine Medical Center Irvine, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, Los Angeles (UCLA) Medical Center Los Angeles, California, United States
  • Scripps Clinic San Diego, California, United States
View all 34 locations
View Trial Details
Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +90 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 21 locations
View Trial Details
Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details
Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

NCT05892718

Conditions
Advanced Solid Tumor, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Hematology-Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
  • Carolina BioOncology Huntersville, North Carolina, United States
  • Greenville Hospital System University Medical Center (ITOR) Greenville, South Carolina, United States
  • UT Southwestern Medical Center Dallas, Texas, United States
View Trial Details

Related conditions